• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Will Quintuple Its Medical Marijuana Production In Germany With New Cultivation License

    7/22/24 1:05:39 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email

    Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday that its Germany cannabis cultivation facility, Aphria RX GmbH, has obtained the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act.

    Why It Matters

    The new cannabis cultivation license allows Aphria RX to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in Germany.

    Denise Faltischek, the company's chief strategy officer and head of international, explained that the license allows Tilray to expand the range of treatment options available to patients. "We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care," Faltischek said.

    Read Also: Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say ‘There’s No Stepping Back’ From Legalization Wave

    Aphria RX was awarded the most comprehensive license for the cultivation of medical cannabis in Germany from the German Federal Institute for Drugs and Medical Devices in May 2019. It was awarded a total of five lots (1,000 kgs) and was the only licensed producer in Germany with permission to grow all three strains of medical cannabis approved by the BfArM.

    Tilray finalized its first harvest of medical cannabis grown in Germany via its German subsidiary Aphria RX in mid-2021. The medical cannabis was distributed to pharmacies in Germany on behalf of the German Cannabis Agency under the country's pharmaceutical and narcotic legal requirements.

    What's Next

    With the new cannabis license, Tilray can fully utilize and maximize its growing capacity while also expanding its genetics to 31 approved strains from the previously approved three strains.

    In the meantime, the new German law on recreational cannabis went into effect on April 1, partially legalizing cannabis by allowing adults over 18 to possess up to 25 grams of dried cannabis and grow three marijuana plants at home.

    Cannabis clubs became legal in Germany on July 1, 2024, ahead of the opening of the first marijuana social club a week later. Lower Saxony Minister of Agriculture Miriam Staudte announced in early July that the permit was awarded by her office to Social Club Ganderkesee.

    Read Next:

    • Aurora & Tilray Better Positioned Than Other Cannabis Operators For Germany’s Imminent Market Launch, Here’s Why

    To learn more about cannabis innovation, com, join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.

    Get the next $TLRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    1/27/2026Hold
    Canaccord Genuity
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    More analyst ratings

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

    Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs  Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027 Tilray's Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1 Conference Call Scheduled for 12:30pm ET NEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly strategic

    3/2/26 10:17:01 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Good Supply Cannabis Brand Expands High-Potency Portfolio with New Spring Lineup Across Canada

    TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that Good Supply, one of Canada's most recognized cannabis brands, has launched its spring product lineup, a new seasonal product release designed to accelerate growth across high-performing formats, including high-potency vapes, flower, and expanded pre-roll offerings. Good Supply's latest product lineup delivers approachable cannabis experiences backed by strong potency, consistent quality, and familiar flavour cues, while expanding consumer choice across multiple

    2/26/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals

    NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with Smartway Pharmaceuticals, a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products across the United Kingdom. Through this agreement, CC Pharma and Smartway will jointly support the expansion of parallel import and specialist pharmaceutical supply in the UK, leveraging Smartway's established national distribution infrastructure to facilitate the delivery of pharmaceutic

    2/12/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    SEC Filings

    View All

    Tilray Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    3/2/26 4:31:58 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Tilray Brands Inc.

    10-Q - Tilray Brands, Inc. (0001731348) (Filer)

    1/8/26 5:03:39 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    1/8/26 4:20:29 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Steven Michael exercised 12,438 shares at a strike of $8.99 (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    1/8/26 4:24:12 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D exercised 706,216 shares at a strike of $0.58 and covered exercise/tax liability with 374,295 shares, increasing direct ownership by 7% to 4,826,493 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:07:08 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A exercised 93,928 shares at a strike of $0.58 and covered exercise/tax liability with 49,782 shares, increasing direct ownership by 5% to 920,497 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 3:12:46 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tilray

    Canaccord Genuity initiated coverage of Tilray with a rating of Hold

    1/27/26 9:29:20 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Alliance Global Partners reiterated coverage on Tilray with a new price target

    Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

    4/5/24 7:39:50 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Tilray with a new price target

    Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

    11/2/22 6:37:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

    ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

    1/23/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

    PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

    10/22/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Financials

    Live finance-specific insights

    View All

    Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

    Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs  Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027 Tilray's Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1 Conference Call Scheduled for 12:30pm ET NEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly strategic

    3/2/26 10:17:01 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

    NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the second fiscal quarter which ended November 30, 2025, after the financial markets close on Thursday, January 8, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of T

    12/22/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2026 Financial Results on October 9, 2025

    NEW YORK and LEAMINGTON, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the first quarter which ended August 31, 2025 before the financial markets open on Thursday, October 9, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Tilray's In

    9/25/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

    SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

    2/13/23 1:34:44 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Tilray Brands Inc.

    SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

    2/10/23 4:41:36 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Tilray Brands Inc.

    SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

    7/22/22 4:30:22 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care